Patent intelligence · US
US 8183204
Methods and compositions for increasing skin remodeling
Methods and compositions for increasing skin remodeling
Patent details — US 8183204
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 22, 2012
- Expiration
- May 17, 2032
- Applicant
- Summit Associates International Inc.
- Claims
- 13
- CPC classes
- A61K, A61K2800/58, A61K38/01, A61K8/19
Quick answer
US 8183204 (Methods and compositions for increasing skin remodeling) is held by Summit Associates International Inc.. Status: granted. Granted May 22, 2012. Expires May 17, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Summit Associates International Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K2800/58, A61K38/01, A61K8/19, A61K8/64
More from Summit Associates International Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12318487
Solid tablet dosage form of ridinilazole
granted -
US 11344575
Vascular calcification prevention and treatment
granted -
US 11007171
Treatment and prevention of joint disorders
granted -
US 9763925
Antibacterial compounds
granted -
US 9492433
Pharmaceutical composition for the treatment of Duchenne muscular dystrophy
granted -
US 9314456
Antibacterial compounds
granted -
US 9278091
Compounds for the treatment of Clostridium difficile associated disease
granted -
US 8987308
Compounds for the treatment of Clostridium difficile-associated disease
granted
Related coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
Frequently asked questions
What is US patent 8183204?
US 8183204 (Methods and compositions for increasing skin remodeling) is held by Summit Associates International Inc.. Status: granted. Granted May 22, 2012. Expires May 17, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8183204?
Summit Associates International Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 8183204 expire?
Our index shows an expiration date of May 17, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.